Font size
click to adjust
Page tools
viva.vita search
viva.vita country websites
Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE » more
Improving the care of people with diabetes
Primary and secondary prevention of diabetes / Focusing on self-care, environment, nutrition, therapy, and exercise » more
Experts Warn of Risk from Changing Parasite Trends in Asia Pacific
Second meeting of the Canine Vector-Borne Diseases (CVBD) and Parasitic Zoonosis Asia Pacific Forum » more
Geri Winkler and the Turquoise Goddess
Diabetic climbs Cho Oyu, the sixth-highest mountain on Earth (8,201 meters) » more
Association of German Medical Journalists (VDMJ) and Bayer HealthCare honor good medical reporting
European Journalists’ Prize 2009 announced » more
Bayer back on the uptrend
HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed » more
Largest international study of treatment outcomes from long-acting injectable testosterone therapy confirms tolerability and effectiveness
New data presented at World Congress on Men's Health » more
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Florbetaben will be used for the very first time in Alzheimer´s patients being treated with a vaccination therapy » more
Bayer’s novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding
Results also confirm significant improvement in blood iron levels » more
Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Preliminary results require further analysis and interpretation » more
First blood glucose monitor with Plug & Play Diabetes Management Software
Bright color display screen / Rechargeable battery / Instructive text messages in native languages / Based on Bayer’s trusted Contour technology » more
First blood glucose designed especially for children
Helping kids to manage their diabetes / Based on Bayer’s trusted Contour technology » more
World Heart Federation and Bayer HealthCare Team Up to “Work with Heart”
Global Focus on Improving Overall Health in the Workplace to Decrease Cardiovascular Disease » more
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany » more
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
Development of the novel anticoagulant rivaroxaban commended / Three research and development teams on shortlist » more
Bayer to supply WHO with a product for the combination therapy of African sleeping sickness
New combination therapy added to the WHO's Essential Drug List » more
Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009 » more
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions » more
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
Werner Wenning extends his contract by eight months / CFO Klaus Kühn to retire on April 30, 2010 / Werner Baumann to be new CFO / BHC CEO Arthur J. Higgins to leave Bayer at his own request » more
Recent Research Supports the Importance of Starting Treatment Early in Patients with Multiple Sclerosis (MS)
New data show impact of hidden symptoms in early MS » more
Betaferon® may play a role in the protection of brain tissue
The multiple sclerosis drug Betaferon® (interferon beta-1b) of Bayer Schering Pharma AG, Germany, may play a role in the protection of brain tissue in patients with multiple sclerosis (MS). » more
Bayer Foundation launches Aspirin Social Award
Dr. Pott, member of the Bayer Board of Management: “We want to reward specific projects and recognize the importance of innovative social work in the health sector” / Closing date for entries is November 30, 2009 / Ideas from the general public increase prize money / Anyone can rate entries online » more